Compare · FMS vs NIVF
FMS vs NIVF
Side-by-side comparison of Fresenius Medical Care AG (FMS) and NewGenIvf Group Limited (NIVF): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both FMS and NIVF operate in Misc Health and Biotechnology Services (Health Care), so they compete in similar markets.
- FMS is the larger of the two at $12.17B, about 39252.1x NIVF ($310,083).
- Over the past year, FMS is down 23.9% and NIVF is down 99.9% - FMS leads by 76.0 points.
- NIVF has been more active in the news (16 items in the past 4 weeks vs 9 for FMS).
- FMS has more recent analyst coverage (21 ratings vs 0 for NIVF).
- Company
- Fresenius Medical Care AG
- NewGenIvf Group Limited
- Price
- $21.79-1.04%
- $0.56-7.80%
- Market cap
- $12.17B
- $310,083
- 1M return
- +0.65%
- -55.73%
- 1Y return
- -23.95%
- -99.90%
- Industry
- Misc Health and Biotechnology Services
- Misc Health and Biotechnology Services
- Exchange
- NYSE
- NASDAQ
- IPO
- News (4w)
- 9
- 16
- Recent ratings
- 21
- 0
Fresenius Medical Care AG
Fresenius Medical Care AG & Co. KGaA provides dialysis care and related dialysis care services in Germany, North America, and internationally. It offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. The company also develops, manufactures, and distributes dialysis products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, and systems for water treatment; and non-dialysis products, such as acute cardiopulmonary and apheresis products. In addition, it develops, acquires, and in-licenses renal pharmaceuticals; offers renal medications and supplies to patients at homes or to dialysis clinics; and provides vascular, cardiovascular, endovascular specialty, vascular care ambulatory surgery center, and physician nephrology and cardiology services. The company sells its products to dialysis clinics, hospitals, and specialized treatment clinics directly, as well as through local sales forces, independent distributors, dealers, and sales agents. As of December 31, 2020, it operated 4,092 outpatient dialysis clinics in approximately 150 countries. Fresenius Medical Care AG & Co. KGaA was incorporated in 1996 and is headquartered in Bad Homburg, Germany.
Latest FMS
- Fresenius Medical Care launches kinexus worldwide, a unified digital platform to support home dialysis
- SEC Form 6-K filed by Fresenius Medical Care AG
- Fresenius Medical Care launches first tranche of its share buyback program of up to EUR 600 million
- SEC Form SD filed by Fresenius Medical Care AG
- Fresenius Medical Care highlights new renal research and innovation at ERA Congress 2026
- SEC Form 6-K filed by Fresenius Medical Care AG
- Fresenius Medical Care announces new share buyback program with a total volume of around EUR 1 billion with phased execution over 12 months
- Fresenius Medical Care Annual General Meeting: Strengthening performance and advancing innovation in kidney care
- Fresenius Medical Care Reappoints Chief Financial Officer Martin Fischer
- SEC Form 6-K filed by Fresenius Medical Care AG
Latest NIVF
- Large owner Hrt Financial Lp sold $50,722 worth of shares (64,945 units at $0.78), decreasing direct ownership by 78% to 18,134 units (SEC Form 4)
- Director Siu Wing Fung Alfred exercised 56,851 units of Class B Ordinary Shares at a strike of $0.00, increasing direct ownership by 189,503% to 56,881 units (SEC Form 4)
- Director Fong Hei Yue Tina exercised 56,851 units of Class B Ordinary Shares at a strike of $0.00, increasing direct ownership by 145,772% to 56,890 units (SEC Form 4)
- Large owner Hrt Financial Lp bought $32,000 worth of shares (34,756 units at $0.92), increasing direct ownership by 72% to 83,079 units (SEC Form 4)
- New insider Hrt Financial Lp claimed ownership of 71,341 shares (SEC Form 3)
- K25.ai Secures US$6 Million Strategic Investment from Nasdaq-Listed NewGen at US$100 Million Valuation; Co-Founders to Join Board and Lead Digital Asset Treasury Strategy
- SEC Form 6-K filed by NewGenIvf Group Limited
- NewGen Doubles Down on K25.ai with Additional US$4 Million Stake and Adopts Digital Asset Treasury Strategy
- Large owner Hrt Financial Lp sold $68,254 worth of shares (85,317 units at $0.80), decreasing direct ownership by 61% to 54,561 units (SEC Form 4)
- SEC Form 6-K filed by NewGenIvf Group Limited